These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15983397)

  • 21. Cancer research. Looking for a target on every tumor.
    Kaiser J
    Science; 2009 Oct; 326(5950):218-20. PubMed ID: 19815749
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
    Ratain MJ; Eckhardt SG
    J Clin Oncol; 2004 Nov; 22(22):4442-5. PubMed ID: 15483011
    [No Abstract]   [Full Text] [Related]  

  • 23. Are targeted therapies really targeted?
    Schilsky RL
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
    [No Abstract]   [Full Text] [Related]  

  • 24. Examining heterogeneity in phase II trial designs may improve success in phase III.
    Tuma RS
    J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
    [No Abstract]   [Full Text] [Related]  

  • 25. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
    Tuma RS
    J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
    [No Abstract]   [Full Text] [Related]  

  • 26. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
    Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
    J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Summary of problems in evaluating effects of cancer chemotherapy].
    Majima H
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):323-5. PubMed ID: 2649006
    [No Abstract]   [Full Text] [Related]  

  • 30. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
    Freidlin B; Simon R
    Clin Cancer Res; 2005 Nov; 11(21):7872-8. PubMed ID: 16278411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 32. [New systemic therapies in oncology].
    Zaman K; Ketterer N; Vulliémoz D; Stupp R; Leyvraz S
    Rev Med Suisse; 2005 May; 1(20):1361-2, 1364-5. PubMed ID: 15991629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.
    Carroll KJ
    Pharm Stat; 2007; 6(4):253-60. PubMed ID: 17351904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
    Blum R; Kloog Y
    Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
    Colevas AD; Scharf O; Schoenfeldt M
    Oncology (Williston Park); 2004 Dec; 18(14):1778, 1781-2, 1784. PubMed ID: 15700626
    [No Abstract]   [Full Text] [Related]  

  • 36. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase II trials in journal of clinical oncology.
    Cannistra SA
    J Clin Oncol; 2009 Jul; 27(19):3073-6. PubMed ID: 19451415
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of genomics in clinical trial design.
    Simon R
    Clin Cancer Res; 2008 Oct; 14(19):5984-93. PubMed ID: 18829477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Facilitating patient-centered cancer research and a new era of drug discovery.
    Niederhuber JE
    Oncologist; 2009 Apr; 14(4):311-2. PubMed ID: 19365096
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.